ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Summary

This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation. ADCT-301 will be administered on Days 1, 8 and 15 with blood tests following study drug infusion. Patients will have a bone marrow biopsy at the end of cycle 2/before cycle 3 to see how they are responding to the study drug. Patients will be followed for approximately every 12 weeks from the last disease assessment for up to 1 year from completion of therapy. There are risks to this study drug. Some risks include: decrease in certain blood cells, weight loss, loss of appetite, rash and Guillain-Barre syndrome, where the immune system attacks and damages nerves.

Timeline

Start

2021-12-07

Primary completion

2022-11-03

Completion

2022-11-03

Outcome

Outcome not reported

Stopped: “ADCT is reallocating all resources to the phase III program.”

Drugs

Indications